Compare · MDT vs NRXS
MDT vs NRXS
Side-by-side comparison of Medtronic plc. (MDT) and Neuraxis Inc. (NRXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and NRXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $117.54B, about 1633.5x NRXS ($72.0M).
- Over the past year, MDT is down 2.3% and NRXS is up 134.0% - NRXS leads by 136.3 points.
- Both names hit the wire about 13 times in the past 4 weeks.
- MDT has more recent analyst coverage (25 ratings vs 0 for NRXS).
- Company
- Medtronic plc.
- Neuraxis Inc.
- Price
- $91.89-0.55%
- $5.71-2.73%
- Market cap
- $117.54B
- $72.0M
- 1M return
- +2.78%
- -17.19%
- 1Y return
- -2.31%
- +134.02%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- AMEX
- IPO
- 2023
- News (4w)
- 13
- 13
- Recent ratings
- 25
- 0
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest MDT
- Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
- Medtronic executives to speak at upcoming investor conferences
- SEC Form 10-Q filed by Medtronic plc.
- SEC Form IRANNOTICE filed by Medtronic plc.
- Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance
- Medtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery
- Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR
- Needham reiterated coverage on Medtronic with a new price target
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 1,084 units of Ordinary Shares, decreasing direct ownership by 0.92% to 116,336 units (SEC Form 4)
Latest NRXS
- iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
- CMO, SVP Science & Tech Miranda Adrian was granted 199,106 shares (SEC Form 4) to satisfy tax liability
- CRO, CCO, CPO Carrico Thomas Joeseph was granted 193,678 shares, increasing direct ownership by 3,418% to 199,345 units (SEC Form 4) (tax liability)
- Chief Executive Officer Carrico Brian Allen was granted 199,188 shares, increasing direct ownership by 708% to 227,336 units (SEC Form 4) to satisfy withholding obligation
- Neuraxis Inc. filed SEC Form 8-K: Leadership Update, Other Events
- Director Watkins Bradley Mitchell was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)
- SEC Form 4 filed by CMO, SVP Science & Tech Miranda Adrian
- Director Keyser Jane Elizabeth was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Henrichs Timothy Robert
- Director Ferge Kristin A was granted 31,134 shares, increasing direct ownership by 87% to 67,072 units (SEC Form 4)